Payment overview · 2025
General Payments
$18.64
1 reported records · 1 companies
Healthcare provider profile · identity verified
Kristen S Murphy, ARNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Adult Health · SATELLITE BEACH, FL · NPI 1649445578
Verified facts
What the public records show
CMS Open Payments records show Kristen S Murphy, ARNP received $18.64 in general payments during 2025 across 1 reported records.
Teva Pharmaceuticals USA, Inc. accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Austedo by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $18.64 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $18.64 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $18.64 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 447 | 60 |
| Atorvastatin Calcium | Atorvastatin Calcium | 311 | 43 |
| Amlodipine Besylate | Amlodipine Besylate | 283 | 43 |
| Gabapentin | Gabapentin | 257 | 34 |
| Trazodone Hcl | Trazodone Hcl | 211 | 35 |
| Pantoprazole Sodium | Pantoprazole Sodium | 209 | 31 |
| Omeprazole | Omeprazole | 201 | 29 |
| Eliquis | Apixaban | 197 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 197 | 25 |
| Potassium Chloride | Potassium Chloride | 195 | 35 |
| Quetiapine Fumarate | Quetiapine Fumarate | 189 | 20 |
| Lisinopril | Lisinopril | 179 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 172 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 170 | 23 |
| Metformin Hcl | Metformin Hcl | 164 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 150 | 19 |
| Losartan Potassium | Losartan Potassium | 149 | 24 |
| Furosemide | Furosemide | 145 | 29 |
| Memantine Hcl | Memantine Hcl | 145 | 27 |
| Donepezil Hcl | Donepezil Hcl | 141 | 22 |
| Sertraline Hcl | Sertraline Hcl | 117 | 20 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 116 | 17 |
| Tramadol Hcl | Tramadol Hcl | 116 | 24 |
| Alprazolam | Alprazolam | 110 | 31 |
| Metoprolol Succinate | Metoprolol Succinate | 108 | 15 |
| Mirtazapine | Mirtazapine | 106 | 14 |
| Divalproex Sodium | Divalproex Sodium | 104 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 97 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 94 | 15 |
| Finasteride | Finasteride | 91 | 12 |
| Montelukast Sodium | Montelukast Sodium | 87 | 11 |
| Famotidine | Famotidine | 78 | 13 |
| Risperidone | Risperidone | 74 | 11 |
| Carvedilol | Carvedilol | 72 | 11 |
| Lorazepam | Lorazepam | 65 | 12 |
| Simvastatin | Simvastatin | 64 | suppressed |
| Levetiracetam | Levetiracetam | 63 | suppressed |
| Xarelto | Rivaroxaban | 63 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 62 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 62 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 61 | 11 |
| Lactulose | Lactulose | 61 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 54 | suppressed |
| Glipizide | Glipizide | 51 | suppressed |
| Olanzapine | Olanzapine | 51 | suppressed |
| Lamotrigine | Lamotrigine | 50 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 49 | suppressed |
| Pregabalin | Pregabalin | 49 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 48 | suppressed |
| Spironolactone | Spironolactone | 48 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 46 | 14 |
| Atenolol | Atenolol | 46 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 46 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 46 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 45 | suppressed |
| Bumetanide | Bumetanide | 42 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 42 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 36 | suppressed |
| Entresto | Sacubitril/Valsartan | 35 | suppressed |
| Januvia | Sitagliptin Phosphate | 35 | suppressed |
| Latanoprost | Latanoprost | 34 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 33 | suppressed |
| Bupropion Xl | Bupropion Hcl | 33 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 33 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 32 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 32 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 32 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 31 | suppressed |
| Myrbetriq | Mirabegron | 30 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 30 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 30 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | suppressed |
| Clonazepam | Clonazepam | 29 | suppressed |
| Methocarbamol | Methocarbamol | 29 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 28 | suppressed |
| Ezetimibe | Ezetimibe | 27 | suppressed |
| Lansoprazole | Lansoprazole | 27 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 27 | 17 |
| Enalapril Maleate | Enalapril Maleate | 26 | suppressed |
| Lovastatin | Lovastatin | 26 | suppressed |
| Nystatin | Nystatin | 26 | 17 |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 25 | suppressed |
| Baclofen | Baclofen | 24 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | 11 |
| Spiriva Handihaler | Tiotropium Bromide | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 22 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 22 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 22 | suppressed |
| Dulera | Mometasone/Formoterol | 21 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 20 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Meloxicam | Meloxicam | 20 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 19 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 12 |
| Enulose | Lactulose | 18 | suppressed |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Sotalol | Sotalol Hcl | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Glimepiride | Glimepiride | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 17 | suppressed |
| Levofloxacin | Levofloxacin | 17 | 16 |
| Lumigan | Bimatoprost | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Naproxen | Naproxen | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 16 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 15 | suppressed |
| Austedo | Deutetrabenazine | 15 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 14 | suppressed |
| Carbamazepine | Carbamazepine | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 14 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 14 | suppressed |
| Methotrexate | Methotrexate Sodium | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 14 | suppressed |
| Torsemide | Torsemide | 14 | suppressed |
| Tradjenta | Linagliptin | 14 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 13 | suppressed |
| Azithromycin | Azithromycin | 13 | 13 |
| Bethanechol Chloride | Bethanechol Chloride | 13 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Celecoxib | Celecoxib | 13 | suppressed |
| Dexamethasone | Dexamethasone | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Fycompa | Perampanel | 13 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 13 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Xifaxan | Rifaximin | 13 | suppressed |
| Zonisamide | Zonisamide | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | suppressed |
| Bicalutamide | Bicalutamide | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Ozempic | Semaglutide | 12 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 11 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 11 | suppressed |
| Invokana | Canagliflozin | 11 | suppressed |
| Jardiance | Empagliflozin | 11 | suppressed |
| Permethrin | Permethrin | 11 | suppressed |
| Trospium Chloride | Trospium Chloride | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
| Zafirlukast | Zafirlukast | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $18.64 · 1 records | Teva Pharmaceuticals USA, Inc. | AUSTEDO XR | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Teva Pharmaceuticals USA, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error